At the time of writing, SAB Biotherapeutics Inc [SABS] stock is trading at $3.99, up 1.01%. An important factor to consider is whether the stock is rising or falling in short-term value. The SABS shares have gain 4.72% over the last week, with a monthly amount glided 4.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SAB Biotherapeutics Inc [NASDAQ: SABS] stock has seen the most recent analyst activity on December 19, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $15. Previously, Leerink Partners started tracking the stock with Outperform rating on September 17, 2025, and set its price target to $7. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $11 on October 09, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $12 as its price target on August 28, 2024. Chardan Capital Markets started tracking with a Buy rating for this stock on November 05, 2021, and assigned it a price target of $17.
For the past year, the stock price of SAB Biotherapeutics Inc fluctuated between $1.00 and $6.60. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. SAB Biotherapeutics Inc [NASDAQ: SABS] shares were valued at $3.99 at the most recent close of the market. An investor can expect a potential return of 75.44% based on the average SABS price forecast.
Analyzing the SABS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.33 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.87 points at the first support level, and at 3.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.08, and for the 2nd resistance point, it is at 4.17.
Ratios To Look Out For
It is important to note that SAB Biotherapeutics Inc [NASDAQ:SABS] has a current ratio of 10.50. On the other hand, the Quick Ratio is 10.50, and the Cash Ratio is 2.73. Considering the valuation of this stock, the price to sales ratio is 1726.82, the price to book ratio is 1.15.
